Highest-materiality recent filing
InnovAge posts investor presentation, reaffirms FY2026 guidance from May 5 press release
Investor presentation posted on company website (https://investor.innovage.com).
InnovAge appoints Jennifer Browne as President & COO effective June 8, 2026
Jennifer Browne appointed President and COO, effective June 8, 2026.
InnovAge Q3 revenue up 15.5% to $251.9M; raises FY2026 guidance
Total revenues $251.9M (+15.5% YoY); net loss $29.9M vs $11.1M loss last year.
InnovAge reaffirms FY2026 guidance at KeyBank Healthcare Forum
Company presenting at KeyBank Capital Markets Healthcare Forum on March 17, 2026.
InnovAge Q2 fiscal 2026 revenue $239.7M (+14.7% YoY), net income $11.8M vs loss $13.5M
Revenue $239.7M up 14.7% YoY; net income $11.8M vs net loss $13.5M in prior year.
InnovAge appoints Pavithra Mahesh and Sean Traynor to Board, expanding to 11 directors
Pavithra Mahesh (Apax Partners Principal) and Sean Traynor (Welsh Carson General Partner) join Board effective Jan 28, 2026.
InnovAge hosts JPM Healthcare Conference investor webcast; presentation furnished
Slide presentation furnished as Exhibit 99.1 for January 12, 2026 investor conference.
InnovAge stockholders elect three Class II directors, ratify auditor at 2025 annual meeting
James G. Carlson, Teresa Sparks, Richard Zoretic elected as Class II directors with >120M 'For' votes each.
InnovAge Q1 FY2026 revenue up 15% to $236M; net income $7.7M vs loss of $5.7M YoY
Revenue $236.1M (+15.1% YoY); net income $7.7M vs loss $5.7M; EPS $0.06 vs -$0.04.
InnovAge President and COO Michael Scarbrough to depart effective November 28, 2025
Michael Scarbrough, President and COO, leaving InnovAge on November 28, 2025.
InnovAge FY2025 revenue up 12% to $853.7M; net loss widens to $30.3M
FY2025 revenue $853.7M (+11.8% YoY); net loss attributable $30.3M ($0.22 loss per share).
New $50.7M Term Loan A and $100M revolving credit facility refinance existing debt under Amended Credit Agreement.
InnovAge Q3 FY2025 revenue $218M (+13% YoY); net loss widens to $0.08/sh
Total revenue $218.1M, up 13.0% YoY; census 7,530 participants vs. 6,820 a year ago.
InnovAge Q2 revenue up 10.6% to $209M, but net loss widens to $13.5M
Total revenue $209.0M, +10.6% YoY; census 7,480 participants (+700 YoY).
InnovAge stockholders elect directors, ratify auditor, approve officer exculpation
Andrew Cavanna, Thomas Scully, Marilyn Tavenner elected as Class I directors with 119.6M, 119.6M, 128.0M votes for, respectively.
InnovAge Q1 revenue $205.1M (+12.4% YoY), net loss narrows to $5.7M from $11.0M
Revenue $205.1M, up 12.4% YoY; center-level contribution margin 16.8% +1.5pp.
InnovAge appoints Michael Scarbrough as President and COO; separates CEO and President roles
Michael Scarbrough appointed President and COO effective Nov 4, 2024; Christine Bent steps down as COO and becomes Senior Advisor through Dec 31.
InnovAge increases share buyback program by $2.5M; total authorization now $7.5M
Board authorized additional $2.5 million share repurchase; total program now $7.5 million.
Total revenue $763.9M, up 11% YoY from $688.1M in FY2023.
InnovAge announces $5M share repurchase program authorized by Board
Board approved repurchase of up to $5.0 million of common stock (NASDAQ: INNV).
InnovAge reports Q3 fiscal 2024 revenue up 12% YoY to $193.1M; net loss narrows to $0.04 EPS
Total revenue $193.1M, up 11.9% YoY from $172.5M; participant census 6,820 vs 6,310 (+8%).
Company held an investor conference via live webcast on February 27, 2024.
InnovAge Q2 revenue up 12.8% to $188.9M; net loss narrows to $3.8M from $10.5M
Revenue $188.9M (+12.8% YoY); participant census 6,780 (+320).
InnovAge grants 250K Class B Units to Chief Legal Officer; re-elects directors, ratifies auditor
Re-elected John Ellis Bush, Patricia Fontneau, and Ted Kennedy Jr. as Class III directors; ratified Deloitte & Touche as auditor.
InnovAge Q1 revenue up 6.6% to $182.5M; adjusted EBITDA turns positive at $2.2M
Total revenue $182.5M, up 6.6% YoY; net loss narrowed to $11.0M from $13.7M.
InnovAge reports FY2023 net loss of $40.7M; revenue down 1.5% to $688.1M
Q4 total revenue $176.9M, net loss $11.2M ($0.09 loss per share); adjusted EBITDA $0.7M.
InnovAge CEO Blair granted 1.1M Class B units of majority shareholder TCO, plus RSUs
CEO Patrick Blair received 1,100,000 Class B units of TCO Group Holdings (company's largest shareholder) on Aug 30, 2023.
InnovAge appoints Teresa Sparks to Board, Sean Traynor resigns
Teresa Sparks appointed as Class II director effective Aug. 14, 2023; will serve until 2025 annual meeting.
InnovAge appoints Ben Adams as CFO effective July 10, replacing Barb Gutierrez
Ben Adams named CFO effective July 10, 2023; base salary $435,000, target bonus 50% of base.
InnovAge Q3 FY2023 revenue down 2.7% to $172.5M; net loss widens to $0.05/share
Total revenue $172.5M, down 2.7% YoY; participant census fell to 6,310 from 6,800.
California DHCS lifts enrollment sanction on InnovAge's Sacramento PACE center
DHCS released Sacramento PACE center from enrollment sanction effective May 1, 2023.
InnovAge appoints Patty Fontneau to Board; two investor directors resign
Patty Fontneau appointed to Board effective March 29, 2023 as Class III director.
Christine Bent appointed COO effective March 20, 2023; replaces Maria Lozzano who becomes Senior Advisor to CEO and COO through August 4, 2023.
InnovAge Q2 FY2023 net loss $10.5M; revenue down 4.5%, Adjusted EBITDA negative $2.0M
Net loss of $10.5M ($0.07 loss per share) vs net income of $1.1M in Q2 FY2022.
CMS and Colorado HCPF lifted enrollment sanctions effective Jan 23, 2023, for InnovAge's six Colorado PACE centers.
Shareholders elected James Carlson, Caroline Dechert, Pavithra Mahesh, and Richard Zoretic as Class II directors.
CMS lifts sanction on InnovAge's Sacramento center; state sanction remains
CMS released sanction effective immediately, allowing normal Medicare enrollment at Sacramento center.
InnovAge Q1 FY23 net loss of $13.7M vs prior-year profit; revenue down 1.1%
Total revenue $171.2M (-1.1% YoY); net loss $13.7M vs net income $7.6M in prior year.
InnovAge sets 2023 annual meeting for Dec 13; shareholder proposal deadline Oct 13
Annual meeting to be held virtually on December 13, 2022.
InnovAge FY2022 revenue $698.6M, net loss $8.0M; no FY2023 guidance
Total revenue $698.6M (+9.5% YoY); net loss $8.0M vs $44.7M loss prior year.
InnovAge appoints James Carlson as non-executive Chairman effective June 30, 2022
Carlson will serve as Class II director and Chairman until the 2023 annual meeting.
InnovAge Q3 revenue up 13.5% to $177.4M; net loss narrows but adjusted EBITDA drops 90%
Net loss $3.2M, EPS -$0.02 diluted vs -$0.09 a year ago; adjusted EBITDA $1.9M vs $20.3M.
InnovAge shareholders elect all three Class I director nominees, ratify auditor
Shareholders elected Andrew Cavanna, Thomas Scully, and Marilyn Tavenner as Class I directors with >122M votes for each.
CMS denies InnovAge's application for Terre Haute PACE center
CMS denial based on deficiencies from 2021 audits of Sacramento and Colorado PACE programs.
Net income $1.1M vs $9.6M YoY; diluted EPS $0.01 vs $0.08.
InnovAge FY2022 annual meeting set for March 17, 2022, virtual format
Annual meeting to be held virtually by remote communication on March 17, 2022.
InnovAge CEO Maureen Hewitt resigns effective Jan 1; Patrick Blair named President and CEO
Maureen Hewitt resigned as CEO and director effective Jan 1, 2022, after 15 years with the company.
CMS suspends new Medicare enrollments at InnovAge Colorado PACE; guidance withdrawn
CMS suspended new Medicare beneficiary enrollment at InnovAge Colorado PACE effective Dec 23, 2021 due to audit deficiencies.
InnovAge appoints Patrick Blair as President, effective Dec 1, 2021
Blair will oversee operations, clinical, sales, marketing, and center development; expansion into 3 new sites in FY2023.
InnovAge Q1 revenue $173.1M (+13.4% YoY); net income $7.6M, EPS $0.06 vs loss $0.41
Total revenues $173.1M, up 13.4% from $152.6M in Q1 fiscal 2021.
On May 11, 2026, the Board of Directors (the “Board”) of InnovAge Holding Corp. (the “Company”) appointed Ms. Jennifer Browne as President and Chief Operating Officer of the Company, effective as of June 8, 2026 (the “Effective Date”).
appointed Michael Scarbrough as President and Chief Operating Officer of the Company, effective as of November 4, 2024
Christine Bent, who departed from the role of the Company’s Chief Operating Officer on October 31, effective as of the Transition Date
Mr. Patrick Blair, the Company’s President and Chief Executive Officer, will cease to serve as the President of the Company and will continue serving as the Company’s Chief Executive Officer
Effective August 14, 2023, the Board of Directors (the “Board”) of InnovAge Holding Corp. (the “Company”) appointed Teresa Sparks as a new member of the Board.
On August 8, 2023, Sean Traynor of Welsh, Carson, Anderson & Stowe (WCAS) resigned from his position as member of the Board.
The Company) appointed Benjamin C. Adams as Chief Financial Officer of the Company effective July 10, 2023 (the “Transition Date”).
Barbara Gutierrez, who will step down from the role of Chief Financial Officer, effective as of the Transition Date, and will remain employed by the Company as Senior Advisor
On March 29, 2023, the Board of Directors (the “Board”) of InnovAge Holding Corp. (the “Company”) appointed Patricia “Patty” Fontneau as a new member of the Board.
On March 29, 2023, Caroline Dechert of Welsh, Carson, Anderson & Stowe (WCAS) and Pavithra Mahesh of Apax Partners each resigned from their positions as members of the Board.
On March 29, 2023, Caroline Dechert of Welsh, Carson, Anderson & Stowe (WCAS) and Pavithra Mahesh of Apax Partners each resigned from their positions as members of the Board.
On March 1, 2023, InnovAge Holding Corp. (the “Company”) announced that its Board of Directors (the “Board”) has appointed Christine Bent as Chief Operations Officer of the Company effective March 20, 2023
Max materiality 0.85 · Median 0.60 · Most common event earnings